PHARMACEUTICAL SOLUTIONS

Gone are the great old blockbuster days. The pharmaceutical industry is on the cusp of a replacement age – with the necessity for personalised therapy, more complex production processes, smaller batch sizes and rising manufacturing costs. it's necessary to continuously adapt to the rapidly changing environment using novel technology and improve operational efficiency and adaptability . And to realize this, intelligent manufacturing seems to be a particular answer. Pharma 4.0,  supported  the concept of Industry 4.0, comprises an amalgamation  of 4  principal technologies that are set to revolutionise manufacturing –  the large  data, computational power and connectivity; the emergence of analytics and business-intelligence capabilities; new  sorts of  human-machine interaction  like  touch interfaces and augmented-reality systems;  and enhancements  in transferring digital instructions to the physical world,  like  advanced robotics and 3-D printing.1 Pharma 4.0  is meant  to for

The concept of modified–release (MR) dosage forms materialised as a neighborhood of the merchandise lifecycle management strategy. The drying pipeline of latest molecules compelled pharmaceutical companies to develop new approaches to retain the exclusivity of patented molecules and gain maximum commercial benefits. This strategy became a huge success setting many companies on the trail where they're now considering the MR approach right at the start of the drug development stage. From a therapeutic perspective, the altered release profile of a drug product does provide a plethora  of advantages  to the patients. It offers  a chance  to modulate the drug concentration  within the  body  to supply  a sustained therapeutic effect over a period. Since MR dosages are required to be taken once  each day  (in most cases), this reduces the dosing frequency significantly,  leading to  better patient compliance. An MR dosage form maintains a steady-state drug plasma concentration  within th